Real-world cost-effectiveness of etonogestrel implants compared to long-term and short term reversible contraceptive methods in France

被引:2
|
作者
Linet, Teddy [1 ]
Levy-Bachelot, Laurie [2 ]
Farge, Gaelle [2 ]
Crespi, Simone [3 ]
Yang, Joe Z. [3 ]
Robert, Julien [4 ]
Fabron, Cecile [4 ]
机构
[1] Ctr Hosp Loire Vendee Ocean, Serv Gynecol Obstetr, Challans, France
[2] Lab MSD France, Puteaux La Defense, France
[3] Merck & Co Inc, Kenilworth, NJ USA
[4] Cemka, Bourg La Reine, France
关键词
Contraceptive methods; contraceptive failure; abortion; cost-effectiveness; etonogestrel implant; long-acting reversible contraceptives; INTRAUTERINE SYSTEM;
D O I
10.1080/13625187.2021.1900562
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background To estimate the cost-effectiveness (CE) of etonogestrel implants compared to other long-term and short-term reversible contraceptive methods available in France. Research design and methods A 6-year Markov model compared effectiveness between the implant and six other contraceptive methods in sexually active, not-pregnancy-seeking French females of reproductive age. Contraception efficacy, switch rates and outcomes were based on French current medical practice. Incremental CE ratios (ICERs) were calculated as incremental cost per unintended pregnancy (UP) avoided. Efficiency frontier was plotted to identify cost-effective methods. Uncertainty was explored through sensitivity analyses. Results The implant was on the efficiency frontier along with combined oral contraceptive pill (COC) and copper IUD. Implant avoids between 0.75% and 3.53% additional UP per person-year compared to copper IUD and second generation COC, respectively, with an ICER of euro2,221 per UP avoided compared to copper IUD. For the 240,000 French women currently using the implant, up to 8,475 UPs and up to 1,992 abortions may be prevented annually. Conclusion With more unintended pregnancies avoided and comparable costs to copper IUD, the implant is a cost-effective option among long-term and short-term reversible contraceptive methods.
引用
收藏
页码:303 / 311
页数:9
相关论文
共 50 条
  • [41] Tobacco cost-effectiveness analyses and the payer: Is the short term long overdue?
    Reed, KE
    Wieck, SG
    Tengs, TO
    VALUE IN HEALTH, 2004, 7 (03) : 325 - 325
  • [42] REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCE
    Bowrin, K.
    Briere, J.
    Millier, A.
    Levy, P.
    Clay, E.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S105 - S105
  • [43] Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
    Bowrin, Kevin
    Briere, Jean-Baptiste
    Fauchier, Laurent
    Coleman, Craig
    Millier, Aurelie
    Toumi, Mondher
    Clay, Emilie
    Levy, Pierre
    PLOS ONE, 2020, 15 (01):
  • [44] Cost-effectiveness analysis in long-term treatment of risk factors
    Szucs, TD
    Gutzwiller, F
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1998, 128 (49) : 1958 - 1964
  • [45] Long-term cost-effectiveness of screening strategies for hearing loss
    Liu, Chuan-Fen
    Collins, Margaret P.
    Souza, Pamela E.
    Yueh, Bevan
    JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2011, 48 (03): : 235 - 243
  • [46] Long-term cost-effectiveness of weight management in primary care
    Trueman, P.
    Haynes, S. M.
    Lyons, G. Felicity
    McCombie, E. Louise
    McQuigg, M. S. A.
    Mongia, S.
    Noble, P. A.
    Quinn, M. F.
    Ross, H. M.
    Thompson, F.
    Broom, J. I.
    Laws, R. A.
    Reckless, J. P. D.
    Kumar, S.
    Lean, M. E. J.
    Frost, G. S.
    Finer, N.
    Haslam, D. W.
    Morrison, D.
    Sloan, B.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (06) : 775 - 783
  • [47] LONG-TERM COST-EFFECTIVENESS OF EUROFIT VERSUS WAITING LIST
    Finch, A. P.
    Wyke, S.
    Kolovos, S.
    van der Ploeg, H.
    van Nassau, F.
    Bosmans, J. E.
    VALUE IN HEALTH, 2018, 21 : S453 - S453
  • [48] Tuberculosis screening for long-term care: a cost-effectiveness analysis
    Verma, G.
    Chuck, A. W.
    Jacobs, P.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (09) : 1170 - 1177
  • [49] COST-EFFECTIVENESS OF COMPONENTS OF COMMUNITY BASED LONG-TERM CARE
    FAVOR, F
    SKELLIE, FA
    GERONTOLOGIST, 1982, 22 : 133 - 133
  • [50] LONG-TERM COST-EFFECTIVENESS OF VALBENAZINE AND DEUTETRABENAZINE FOR TARDIVE DYSKINESIA
    Harrigan, K.
    Walton, S. M.
    Huang, S. P.
    Kumar, V. M.
    Chapman, R. H.
    Atlas, S. J.
    Agboola, F. O.
    Ollendorf, D. A.
    Touchette, D. R.
    VALUE IN HEALTH, 2018, 21 : S184 - S184